FrancophonIA/ELRC3.0 huggingface dataset:
English: Why is Rasagiline Mylan approved?
Croatian: Zašto je Rasagiline Mylan odobren?
English: For practical information about using Rasagiline Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o korištenju lijeka Rasagiline Mylan bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: Because Rasagiline Mylan is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Azilect.
Croatian: Budući da je Rasagiline Mylan generički lijek, ispitivanja na bolesnicima bila su ograničena na ispitivanja za utvrđivanje njegove bioekvivalentnosti s referentnim lijekom Azilect.
English: Other information about Rasagiline Mylan
Croatian: Ostale informacije o lijeku Rasagiline Mylan
English: Therefore, the CHMP's view was that, as for Azilect, the benefit outweighs the identified risk.
Croatian: Stoga je stav CHMP-a kako koristi nadmašuju utvrđeni rizik, kao i kod lijeka Azilect.
English: Rasagiline Mylan contains the active substance rasagiline.
Croatian: Rasagiline Mylan sadrži djelatnu tvar razagilin.
English: How does Rasagiline Mylan work?
Croatian: Kako djeluje Rasagiline Mylan?
English: How is Rasagiline Mylan used?
Croatian: Kako se koristi Rasagiline Mylan?
English: How has Rasagiline Mylan been studied?
Croatian: Kako je Rasagiline Mylan ispitivan?
English: Intramuscular use vial (glass)
Croatian: Intramuskularna primjena bočica (staklena)
English: Powder for solution for injection
Croatian: 100 jedinica Prašak za otopinu za injekciju
English: 100 tablets
Croatian: 100 tablete
English: Immediate Packaging Pack size bottle (HDPE)
Croatian: (Zaštićeno) ime Jačina Farmaceutski oblik Put primjene Unutarnje pakovanje Veličina pakovanja EU/1/15/1054/001 Cinacalcet Mylan 30 mg Filmom obložena tableta bočica (HDPE)
English: EU/2/14/172/002
Croatian: EU/2/14/172/001 EU/2/14/172/002
English: ATC vet code: QI07AI08.
Croatian: ATCvet kod: QI07AI08.
English: Date of last renewal: 11/04/2019.
Croatian: Datum posljednjeg produljenja odobrenja: 11/04/2019.
English: Komenského 212, 683 23 Ivanovice na Hané, CZECH REPUBLIC
Croatian: Komenského 212, 683 23 Ivanovice na Hané,
English: In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Croatian: U nedostatku studija kompatibilnosti, ovaj veterinarsko - medicinski proizvod ne smije se miješati s drugim veterinarsko-medicinskim proizvodom.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Croatian: vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavu(e)), - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja), - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja), - rijetke (više od 1 ali manje od 10 životinja na 10.000 tretiranih životinja), - vrlo rijetke (manje od 1 životinje na 10.000 tretiranih životinja, uključujući izolirane slučajeve).
English: Potassium chloride Potassium dihydrogen phosphate Disodium phosphate dodecahydrate Water for injections
Croatian: Kalijev dihidrogen fosfat Dinatrijev fosfat dodekahidrat Voda za injekcije
English: Duration of immunity: At least one year following the primary vaccination course for all components of Versican Plus Pi/L4.
Croatian: Najmanje godinu dana nakon osnovnog cijepljenja za sve komponente Versican Plus Pi/L4.
English: Adjuvant: Aluminium hydroxide
Croatian: Aluminijev hidroksid
English: Minimum Maximum Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15 10
Croatian: Minimalno Maksimalno Pseći parainfluenca virus tip 2, soj CPiV-2 Bio 15 10
English: The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine parainfluenza virus, Leptospira interrogans serogroup Australis serovar Bratislava, Leptospira interrogans serogroup Canicola serovar Canicola, Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa and Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae.
Croatian: Cjepivo je namijenjeno aktivnoj imunizaciji zdrave štenadi i zdravih pasa protiv bolesti koje uzrokuje pseći virus parainfluence, Leptospira interrogans, serotip Australis, serovar Bratislava, Leptospira interrogans, serotip Canicola, serovar Canicola, Leptospira kirschneri, serotip Grippotyphosa, serovar Grippotyphosa, i Leptospira interrogans, serotip Icterohaemorrhagiae, serovar Icterohaemorrhagiae.
English: − to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus,
Croatian: − sprječavanje kliničkih znakova (iscjedak iz nosa i očiju) i smanjivanje izlučivanja virusa uzrokovanih virusom parainfluence,
English: The live attenuated virus vaccine strain CPiV may be shed by vaccinated animals following vaccination.
Croatian: Živo atenuirano virusno cjepivo može se proliti nakon cijepljenja.
English: Primary vaccination scheme: Two doses of Versican Plus Pi/L4 3-4 weeks apart from 6 weeks of age.
Croatian: Dvije doze Versican Plus Pi/L4 u razmaku od 3-4 tjedna nakon navršenih 6 tjedana starosti.
English: Suspension: whitish colour with fine sediment.
Croatian: Suspenzija: bjelkaste boje s sitnim talogom.
English: A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Croatian: Odluku o primjeni ovog cjepiva prije, odnosno poslije primjene bilo kojeg drugog veterinarsko-medicinskog proizvoda treba donositi od slučaja do slučaja od strane veterinara.
English: − 4 weeks after the completion of primary course for Leptospira components.
Croatian: - 3 tjedna nakon završetka osnovnog cijepljenja za CPiV i - 4 tjedna nakon završetka osnovnog cijepljenja za komponente leptospire.
English: − 4 weeks after completion of the primary course for Leptospira components.
Croatian: - 3 tjedna nakon završetka osnovnog cijepljenja za CPiV i - 4 tjedna nakon završetka osnovnog cijepljenja za komponente Leptospire.
English: Reconstituted vaccine: pinkish or yellowish colour with a slight opalescence.
Croatian: Rekonstituirano cjepivo: ružičaste do žućkaste boje s blagom opalescencijom.
English: Re-vaccination scheme: A single dose of Versican Plus Pi/L4 to be given annually.
Croatian: Jedna doza Versican Plus Pi/L4 godišnje.
English: PHARMACEUTICAL FORM Lyophilisate and suspension for suspension for injection
Croatian: Liofilizat i suspenzija za suspenziju za injekciju
English: 4.2 Indications for use, specifying the target species Active immunisation of dogs from 6 weeks of age:
Croatian: INDIKACIJE Aktivna imunizacija pasa starijih od 6 tjedana:
English: PACKAGE LEAFLET: Versican Plus Pi/L4 lyophilisate and suspension for suspension for injection for dogs
Croatian: Versican Plus Pi/L4 liofilizat i suspenzija za suspenziju za injekciju za pse
English: ALR ** titre ≥ 1:40
Croatian: ALR** titar ≥ 1:40
English: − to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae and
Croatian: interrogans, serotip Canicola, serovar Canicola i L. interrogans, serotip Icterohaemorrhagiae, serovar Icterohaemorrhagiae i
English: ALR ** titre ≥ 1:51
Croatian: ALR** titar ≥ 1:51
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus Pi/L4 suspension for dogs
Croatian: Versican Plus Pi/L4 suspenzija za pse
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus Pi/L4 lyophilisate for dogs
Croatian: Versican Plus Pi/L4 liofilizat za pse
English: Suspension (inactivated):
Croatian: Docjepljivanje (revakcinacija):
English: No other adverse reactions other than those mentioned in section 4.6 were observed after administration of a 10-fold overdose of the vaccine.
Croatian: 4.10 Predoziranje (simptomi, hitni postupci, antidoti), ako je nužno Nakon primjene deseterostruke propisane doze nisu zapažene druge nuspojave osim onih navedenih u odjeljku 4.6. Međutim, kod manjeg broja pasa uočena je bolnost na mjestu aplikacije odmah po primjeni deseterostruke doze.
English: Lyophilisate: Trometamol Edetic acid Sucrose Dextran 70
Croatian: EDTA - etilendiamintetraoctena kiselina Saharoza
English: The visual appearance is as follows:
Croatian: Učestalost nuspojava je određena sukladno sljedećim pravilima:
English: Article 34 of Directive 2001/82/EC, as amended
Croatian: Direktive 2001/82/EZ, dopunjeno
English: International non-proprietary name (INN): tilmicosin
Croatian: Međunarodni nezaštićeni naziv (INN): tilmikozin
English: The referral procedure started on 15 May 2012.
Croatian: Postupak upućivanja započeo je 15. svibnja 2012.
English: The Committee appointed Mr G. Johan Schefferlie as rapporteur and Dr Michael Holzhauser-Alberti as co-rapporteur.
Croatian: Johana Schefferliea kao procjenitelja i gospodina dr. Michaela Holzhauser-Albertija kao pomoćnog procjenitelja.
English: Written explanations were provided by the marketing authorisation holders on 18 September 2012, 11 February 2013 and 26 May 2013.
Croatian: Nositelj odobrenja podnio je pisana objašnjenja 18. rujna 2012., 11. veljače 2013. i 26. svibnja 2013.
English: Due to divergent national decisions taken by Member States concerning the authorisations of Micotil 300 Injectie and its associated names, on 24 April 2012 the Netherlands referred the issue to the CVMP under Article 34(1) of Directive 2001/82/EC, in order to resolve discrepancies in the product information across the European Union.
Croatian: Zbog divergentnih odluka koje su države članice donijele vezano uz odobrenje lijeka Micotil 300 Injectie i njegovih srodnih naziva, Nizozemska je 24. travnja 2012. predmet uputila Povjerenstvu za veterinarske lijekove (CVMP) u skladu s člankom 34. stavkom 1. Direktive 2001/82/EZ, s ciljem rješavanja neusklađenosti u informacijama o tom proizvodu diljem EU-a.
English: Tilmicosin is a macrolide antibiotic synthesized from tylosin which has an antibacterial spectrum similar to tylosin with enhanced activity against Pasteurella multocida and Mannheimia haemolytica.
Croatian: Tilmikozin je makrolidni antibiotik sintetiziran od tilosina koji ima antibakterijski spektar sličan tilozinu s pojačanim djelovanjem protiv mikroba Pasteurella multocida i Mannheimia haemolytica.
English: The final opinion was converted into a Decision by the European Commission on 18 October 2013.
Croatian: Europska komisija to je mišljenje pretvorila u svoju odluku 18. listopada 2013.
English: Micotil 300 Injectie and its associated names are veterinary medicinal products authorised for use in the target species cattle, sheep and rabbits for treatment of various infections caused by microorganisms susceptible to tilmicosin.
Croatian: Micotil 300 Injectie i njegovi srodni nazivi jesu veterinarski lijekovi odobreni za upotrebu kod goveda, ovaca i kunića za liječenje raznih infekcija uzrokovanim mikroorganizmima osjetljivih na tilmikozin.
English: Oral explanations were given on 11 June 2013.
Croatian: Usmena su objašnjenja dana 11. lipnja 2013.
English: The Committee adopted a positive opinion by consensus on 18 July 2013.
Croatian: Povjerenstvo je jednoglasno usvojilo pozivno mišljenje 18. srpnja 2013.
English: Based on the currently available data, the CVMP considered that the benefit-risk profile of Micotil 300 Injectie and its associated names remains positive, subject to variation of the marketing authorisations in accordance with the recommended product information.
Croatian: Na temelju trenutno dostupnih podataka, CVMP smatra da omjer rizika i koristi za lijek Micotil 300 Injectie kao i za njegove srodne nazive i dalje ostaje pozitivan, podložan izmjenama odobrenja u skladu s preporučenim informacijama o lijeku.
English: Micotil 300 Injectie is a solution for injection containing tilmicosin with a strength of 300 mg per ml.
Croatian: Micotil 300 Injectie je otopina za injekciju koja sadrži tilmikozin koncentracije 300 mg po ml.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended Summary of Product Characteristics, labelling and package leaflet in Annex III.
Croatian: Znanstveni zaključci nalaze se u Prilogu II. zajedno s dopunjenim Sažetkom opisa svojstava lijeka, označavanja i uputi o lijeku u Prilogu III.
English: 18 October 2013
Croatian: 18. listopada 2013. EMA/539469/2013
English: Opinion following an Article 341 referral for Micotil 300 Injectie and its associated names
Croatian: Mišljenje prema članku 34.1 upućivanje za lijek Micotil
English: Opinion following an Article 340F referral for Micotil 300 Injectie and its associated names
Croatian: Mišljenje prema članku 34.0F upućivanje za lijek Micotil 300 Injectie i njegove srodne nazive EMA/696374/2013
English: 270 capsules blister (PVC/Aclar (PCTFE)) Initiation pack: 63 (1 x 21 and 2 x 21) tablets
Croatian: Pakiranje za početak liječenja: 63 (1 x 21 i 2 x 21) tablete
English: Immediate Packaging Pack size blister (PVC/PE/PCTFE/alu) Initiation pack: 63 (7 x 3 and 7 x 6) capsules blister (PVC/PE/PCTFE/alu) 252 x 1 capsules (unit dose)
Croatian: Pakiranje za početak liječenja: 63 (7 x 3 i 7 x 6) kapsule
English: Route of Administration
Croatian: 270 kapsula
English: Further information on Instanyl can be found on the Agency's website: ema.europa.eu/medicines/Human/EPAR/Instanyl.
Croatian: Više informacija o lijeku Instanyl možete naći na internetskim stranicama Agencije: ema.europa.eu/medicines/Human/EPAR/Instanyl.
English: The medicine can only be obtained by ‘special' prescription.
Croatian: Lijek se izdaje samo na „poseban” liječnički recept.
English: What is Instanyl what is it used for?
Croatian: Što je Instanyl i za što se koristi?
English: This overview was last updated in 03-2019
Croatian: Ovaj pregled informacija posljednji je put ažuriran: 03. 2019.
English: What measures are being taken to ensure the safe and effective use of Instanyl?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Instanyl?
English: Instanyl received a marketing authorisation valid throughout the EU on 20 July 2009.
Croatian: Lijek Instanyl dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 20. srpnja 2009.
English: It is available in singledose containers and in multidose containers.
Croatian: Dostupan je u jednodoznim spremnicima i višedoznim spremnicima.
English: It must not be used to treat short-term pain other than breakthrough pain.
Croatian: Ne smije se koristiti za liječenje kratkoročne boli osim probojne boli.
English: The doctor should keep in mind the potential for Instanyl to be abused.
Croatian: Liječnik treba imati na umu mogućnost zlouporabe lijeka Instanyl.
English: It is a well-known substance, which has been used to control pain for many years.
Croatian: To je dobro poznata tvar koja se koristi za kontrolu boli tijekom dugog niza godina.
English: Why is Instanyl authorised in the EU?
Croatian: Zašto je lijek Instanyl odobren u EU-u?
English: A patient's breakthrough pain was considered to have responded to treatment if there was a reduction of at least 2 points.
Croatian: Smatralo se da je probojna bol bolesnika odgovorila na liječenje ako je nastupilo smanjenje od najmanje dva boda.
English: Other information about Instanyl
Croatian: Ostale informacije o lijeku Instanyl
English: What are the risks associated with Instanyl?
Croatian: Koji su rizici povezani s lijekom Instanyl?
English: As for all medicines, data on the use of Instanyl are continuously monitored.
Croatian: Kao za sve lijekove, podatci o primjeni lijeka Instanyl kontinuirano se prate.
English: For more information about using Instanyl, see the package leaflet or contact your doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Instanyl pogledajte uputu o lijeku ili se obratite liječniku ili ljekarniku.
English: An overview of Instanyl and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Instanyl i zašto je odobren u EU-u
English: Because fentanyl has been in use for many years, the company presented data from the scientific literature, as well as from studies that it had carried out, which showed that Instanyl was more effective than placebo (a dummy treatment) at treating breakthrough pain in cancer patients.
Croatian: S obzirom na to da se fentanil koristi već dugi niz godina, tvrtka je dostavila podatke iz znanstvene literature kao i iz ispitivanja koja je provela, koji su pokazali da je lijek Instanyl učinkovitiji od placeba (prividno liječenje) u liječenju probojne boli u bolesnika s rakom.
English: The most common side effects with Instanyl (which may affect up to 1 in 10 people) are somnolence (sleepiness), dizziness, headache, vertigo (a spinning sensation), flushing (reddening of the skin), hot flushes, throat irritation, nausea (feeling sick), vomiting and hyperhidrosis (excessive sweating).
Croatian: Najčešće nuspojave lijeka Instanyl (koje se mogu javiti u najviše 1 na 10 osoba) su somnolencija (pospanost), omaglica, glavobolja, vrtoglavica (osjećaj vrtnje), rumenilo (crvenilo kože), napadaji vrućine, nadraženost grla, mučnina, povraćanje i hiperhidroza (prekomjerno znojenje).
English: Side effects reported with Instanyl are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Instanyl pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: In one main study, 178 adult cancer patients with breakthrough pain took one spray of either Instanyl (50, 100 or 200 microgram) or placebo when they experienced breakthrough pain.
Croatian: U jednom glavnom ispitivanju, 178 odraslih bolesnika oboljelih od raka s probojnom boli primilo je jednu dozu lijeka Instanyl (50, 100 ili 200 mikrograma) ili placebo (prividno liječenje) kad su osjetili probojnu bol.
English: Side effects are similar to those of other medicines containing fentanyl, and measures have been put in place to minimise the risk of misuse and overdose.
Croatian: Nuspojave su slične onima kod drugih lijekova koji sadrže fentanil te su uspostavljene mjere minimizacije rizika od zlouporabe i predoziranja.
English: If there has been insufficient pain relief, the same dose can be given again at the earliest after 10 minutes.
Croatian: Ako bol nije ublažena u dostatnoj mjeri, ista se doza može ponoviti najranije nakon deset minuta.
English: The European Medicines Agency decided that Instanyl's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi lijeka Instanyl nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: When the patient sprays Instanyl into the nose, a dose of fentanyl is absorbed into the blood stream through the blood vessels in the nose.
Croatian: Nakon što bolesnik uštrca Instanyl u nos, doza fentanila apsorbira se u krvotok putem krvnih žila u nosu.
English: The patient should be given Instanyl for a maximum of 4 episodes of breakthrough pain a day.
Croatian: Bolesniku se treba dati lijek Instanyl za najviše četiri epizode probojne boli na dan.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Instanyl have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Instanyl nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: In a third study, which involved 139 patients and compared Instanyl with ‘transmucosal' fentanyl (absorbed through the lining of the mouth), patients who received Instanyl had faster pain relief than patients who received transmucosal fentanyl .
Croatian: U trećem ispitivanju, koje je obuhvatilo 139 bolesnika i u kojem je lijek Instanyl uspoređen s fentanilom za „transmukoznu” primjenu (apsorbira se kroz sluznicu usta), u bolesnika koji su primali lijek Instanyl došlo je do bržeg smanjenja boli nego u bolesnika koji su primali transmukozni fentanil.
English: Each patient then used the identified dose of Instanyl or placebo to treat breakthrough pain.
Croatian: Svaki je bolesnik zatim koristio utvrđenu dozu lijeka Instanyl ili placeba za liječenje probojne boli.
English: In another main study, 128 patients were given increasing doses of Instanyl until the adequate dose for pain relief was reached.
Croatian: U drugom glavnom ispitivanju, 128 bolesnika primalo je rastuće doze lijeka Instanyl sve dok nije dosegnuta odgovarajuća doza za ublažavanje boli.
English: Instanyl is available as a nasal spray (50, 100 and 200 micrograms per dose).
Croatian: Lijek Instanyl dostupan je u obliku spreja za nos (50, 100 i 200 mikrograma po dozi).
English: Before starting treatment with Instanyl, the patient's long-term pain should be well controlled by opioid pain killers and they should have no more than 4 episodes of breakthrough pain a day.
Croatian: Prije započinjanja liječenja lijekom Instanyl, kronična bol bolesnika treba se dobro kontrolirati opioidnim analgeticima te bolesnici ne smiju imati više od četiri epizode probojne boli na dan.
English: The company that markets Instanyl will also provide educational materials to be supplied to patients, doctors and pharmacists, explaining the correct and safe use of the medicine.
Croatian: Tvrtka koja stavlja lijek Instanyl u promet također će dostaviti edukativne materijale s informacijama o ispravnoj i sigurnoj primjeni lijeka bolesnicima, liječnicima i ljekarnicima.
English: This means that because the medicine can be misused or cause addiction, it is used under stricter conditions than normal.
Croatian: To znači da se lijek primjenjuje pod strožim uvjetima od normalnih jer se može zlouporabiti odnosno uzrokovati ovisnost.
English: Breakthrough pain is when a patient experiences additional, sudden pain in spite of ongoing treatment with painkillers.
Croatian: Probojna bol je dodatna, iznenadna bol koju bolesnik osjeti usprkos kontinuiranom liječenju analgeticima.
English: Instanyl contains the active substance fentanyl.
Croatian: Instanyl sadrži djelatnu tvar fentanil.
English: The change in pain intensity after 10 minutes was between 2.0 and 2.7 points after receiving doses of Instanyl compared with 1.3 after receiving placebo.
Croatian: Promjena u intenzitetu boli nakon deset minuta bila je između 2,0 i 2,7 bodova nakon doza lijeka Instanyl, u usporedbi s 1,3 nakon placeba.
English: Patients taking Instanyl were allowed to take a second spray 10 minutes after the first dose if there had been insufficient pain relief.
Croatian: Bolesnicima koji su uzimali lijek Instanyl dopuštena je druga doza spreja deset minuta nakon prve doze ako ublažavanje boli nije bilo dostatno.
English: Once in the bloodstream, fentanyl acts on receptors in the brain and spinal cord to relieve pain.
Croatian: Nakon što dospije u krvotok, fentanil djeluje na receptore u mozgu i leđnoj moždini kako bi ublažio bol.
English: The reduction in pain intensity after 10 minutes was between 1.8 and 2.7 points on an 11-point pain scale for patients who took Instanyl, compared with 1.4 for patients who took placebo.
Croatian: Smanjenje intenziteta boli nakon deset minuta bilo je između 1,8 i 2,7 bodova na ljestvici boli od 11 bodova u bolesnika koji su primali lijek Instanyl, u usporedbi s 1,4 u bolesnika koji su primali placebo.
English: What benefits of Instanyl have been showed in studies?
Croatian: Koje su koristi lijeka Instanyl utvrđene u ispitivanjima?